Illumina shares plunge as it cuts Q1 outlook
April 20, 2016Research and Development, Sales and Marketing Financial, Illumina, Share price, Shares, outlook, revenue, stock market
Shares in Illumina (Nasdaq: ILMN) plunged after the company cut its revenue estimates for the first quarter based on low …
Focus: Bristol-Myers Squibb’s wonder drug – Opdivo
April 20, 2016Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales
By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure
April 20, 2016Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly
Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …
Boehringer Ingelheim posts 11% rise in FY15 sales boosted by diabetes business
April 20, 2016Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, FY, earnings, forecasts, outlook, results
Boehringer Ingelheim reported 11% jump in sales for 2015 driven by its diabetes business and said for 2016 it sees …
Gilead presents data highlighting progress and efficacy in liver and hepatitis C therapies
April 20, 2016Research and Development, Sales and Marketing Gilead, harvoni, hepatitis, liver, sofosbuvir
Gilead (NASDAQ: GILD) has presented a broad range of results on its current and potential therapeutics at the International Liver …
J&J raises FY outlook, Q1 beats estimates
April 20, 2016Business Services, Research and Development, Sales and Marketing Financial, Johnson & Johnson, Q1, earnings, results, revenue, sales
Healthcare giant Johnson & Johnson (NYSE: JNJ) raised its full-year outlook and posted first-quarter earnings ahead of estimates despite currency headwinds. …
Lemtrada shows clinical efficacy in multiple sclerosis in 10-year follow-up data
April 20, 2016Research and Development, Sales and Marketing Lemtrada, Sanofi, alemtuzumab, multiple sclerosis, sanofi genzyme
Sanofi Genzyme has presented 10-year follow-up data on Lemtrada (alemtuzumab) which points to its efficacy in patients with relapsing-remitting multiple …
Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin
April 19, 2016Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial
New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
Bristol-Myers Squibb’s Opdivo shows positive results in early stage trials for advanced skin cancer
April 19, 2016Manufacturing and Production, Research and Development Bristol-Myers Squibb, drug trial, immuno-therapy, oncology, opdivo
New data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat advanced melanoma showed overall survival of five years in 34% patients, …
Opdivo shows biggest survival increase for head and neck cancer in 20 years in Phase III trials
April 19, 2016Research and Development, Sales and Marketing Bristol-Myers Squibb, Cancer, blockbuster, head and neck cancer, nivolumab, oncology, opdivo, potential, squamous
Opdivo (nivolumab) showed the biggest increase in survival for patients with head and neck cancer for 20 years, according to …
Roche reports 5% rise in Q1 sales boosted by cancer drugs
April 19, 2016Manufacturing and Production, Sales and Marketing Q1, Roche, earnings, oncology drugs, results
Oncology drug maker Roche (VTX: ROG) on Tuesday reported 5% increase in first-quarter sales driven by cancer drugs. The company …
GlaxoSmithKline opens new £56 million facility in Hertfordshire
April 19, 2016Manufacturing and Production Andrew Witty, GSK, GlaxoSmithKline, Sir Andrew Witty, ellipta, facility, george freeman, inhalers, manufacturing, new, respiratory, ware
GlaxoSmithKline has opened a new £56 million manufacturing facility in Hertfordshire, South-East England. The facility in Ware will create 150 …
Eli Lilly drops development of diabetes drug in Phase III
April 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing Eli Lilly, Transition Therapeutics, diabetes, drug trial
US drugmaker Eli Lilly (NYSE: LLY) has pulled out of the partnership with Transition Therapeutics (TSX: TTH) to develop its …
MSD receives fourth Breakthrough Therapy Designation for Keytruda
April 19, 2016Manufacturing and Production, Research and Development Breakthrough Therapy Designation, FDA, Hodgkin lymphoma, MSD, Merck, breakthrough designation, breakthrough therapy, keytruda
MSD (NYSE: MRK) has announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation to Keytruda (pembrolizumab) …
Sanofi invests €300 million in new Belgian biologics site
April 19, 2016Manufacturing and Production Belgium, Sanofi, belgian, flanders, geel, investment, manufacturing, pipeline
Sanofi has announced plans to expand its site in Geel, Belgium, with a €300 million investment to support its pipeline …
FDA rejects Chiasma’s new drug application for therapy to treat rare growth disorder
April 18, 2016Research and Development, Sales and Marketing Chiasma Inc, US FDA, drug trial, rare disease
Shares in Chiasma Inc (Nasdaq: CHMA) plunged to more than halve on the Nasdaq Monday as the company reported the …
Novo unveils new research grant to mark World Haemophilia Day
April 18, 2016Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
British Biosimilars Association launches in UK
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing ABPI, Napp, bba, bgma, british biosimilars association
A new industry body, the British Biosimilars Association, has been formally launched today with the sole focus of increasing the …
Weekly Movers: Valeant, Depomed, Intercept Pharma, Insys Therapeutics and more…
April 18, 2016Manufacturing and Production, Research and Development, Sales and Marketing Depomed, Intercept Pharma, Relypsa, Share price, Stock Movement, Valeant, stock market
Troubles don’t seem to go away for Canada-based Valeant Pharma (NYSE: VRX) with news of a probable sale doing the …
Sticking the boot in
April 18, 2016Sales and Marketing Boots, Cost, Guardian, NHS, prescribing, scandal, unfair
A recent exposé has shone a light on the practices allegedly enforced at the nation’s largest pharmacy. So what exactly …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
